FindTrial
Sign In

A randomized, investigator blind, split-face study of the efficacy of using Eucerin Dermopure to reduce mucocutaneous side effects of adapalene/benzoyl peroxide combination (Epiduo) for the treatment of acne vulgaris.

A randomized, investigator blind, split-face study of the efficacy of using Eucerin Dermopure to reduce mucocutaneous side effects of adapalene/benzoyl peroxide combination (Epiduo) for the treatment of acne vulgaris.

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20210709005
Enrollment
30
Registered
2021-07-09
Start date
2021-08-02
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne vulgaris Eucerin Dermopure, irritation, mucocutaneous side effects, acne treatment, acne vulgaris

Interventions

Eucerin dermopure,Hydrophilic cream
Experimental Drug,Active Comparator Drug

Sponsors

Beiersdorf Thailand
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Acne vulgaris patient

Exclusion criteria

Exclusion criteria: lactation, pregnancy, allergy to study product, use of drug-induced acne, Polycystic Ovary Syndrome (PCOS)

Design outcomes

Primary

MeasureTime frame
Irritation score week 0, week 2, week 4 interview—

Secondary

MeasureTime frame
Skin biophysics week 0, week 2, week 4 Corneometer, tewameter, pH meter ,Erythema score week 0, week 2, week 4 Visia,Patient satisfaction week 0, week 2, week 4 Patient satisfaction score—

Countries

Thailand

Contacts

Public ContactPawinee Rerknimitr

Faculty of Medicine,Chulalongkorn University

pawineererk@yahoo.co.th022564253

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026